CEL-SCI (CVM) Stock Price, News & Analysis

Company Overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Key Stats

• Today's Range: $2.40 to $2.57
• 50-Day Range: $2.46 to $9.18
• 52-Week Range: $2.32 to $66.60
• Volume: 715,232 shs
• Average Volume: 49,893 shs
• Market Capitalization: $228.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CVM Stock Analysis - Frequently Asked Questions

How have CVM shares performed this year?

CEL-SCI's stock was trading at $11.9970 at the beginning of 2025. Since then, CVM shares have decreased by 79.1% and is now trading at $2.51.
View the best growth stocks for 2025 here.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSE:CVM) released its quarterly earnings results on Thursday, August, 15th. The company reported ($4.20) earnings per share for the quarter, missing the consensus estimate of ($3.90) by $0.30.

When did CEL-SCI's stock split?

Shares of CEL-SCI reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's major shareholders?

CEL-SCI's top institutional shareholders include MAI Capital Management (0.63%). Insiders that own company stock include Geert R Kersten, Patricia B Prichep and Robert Eugene Watson.
View institutional ownership trends.

How do I buy shares of CEL-SCI?

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 5/24/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CVM
• CIK: 725363
• Web: cel-sci.com
• Phone: 703-506-9460
• Fax: 703-506-9471
• Employees: 43
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-26,920,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.05%
• Return on Assets: -104.65%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 1.07
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 16.73

Miscellaneous

• Outstanding Shares: 91,037,000
• Free Float: 64,673,000
• Market Cap: $228.50 million
• Optionable: Optionable
• Beta: 0.50